11:44 AM EDT, 08/13/2024 (MT Newswires) -- Genprex ( GNPX ) said Tuesday it received a patent in Singapore covering the use of the company's Reqorsa lead drug candidate to treat cancers in combination with anti-PD-1 antibodies through 2037.

The company said it will pursue additional patent applications with claims to combinations of Reqorsa and PD-L1 antibodies in the US, Brazil, Canada, China, Europe and Israel.

If granted, the applications would be applicable to Genprex's ( GNPX ) Acclaim-3 clinical trial. The company said the phase 1/2 study uses Reqorsa and Genentech's Tecentriq as maintenance therapy for patients with extensive-stage small-cell lung cancer who developed tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.

Genprex ( GNPX ) shares were down 25% in recent trading.

Price: 0.95, Change: -0.32, Percent Change: -24.88